TED-347
Based on 11 publication(s) in Google Scholar
TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity.
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 2378626-29-8
- Formula: C15H11ClF3NO
- Molecular Weight:313.70
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Cysteine Targeted Covalent Library
HY-L153
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) TED-347
More- Signal Transduct Target Ther. 2024 Mar 9;9(1):65. [Abstract]
- Nat Commun. 2024 Nov 16;15(1):9950. [Abstract]
- J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]
- Prog Orthod. 2024 Aug 12;25(1):29. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2026 Mar;1873(3):120111. [Abstract]
- Exp Dermatol. 2022 Oct;31(10):1477-1499. [Abstract]
- FEBS Lett. 2022 Feb;596(4):449-464. [Abstract]
- PLoS One. 2024 Jul 31;19(7):e0305121. [Abstract]
- Res Sq. 2025 May 15.
- bioRxiv. 2025 April 14.
- bioRxiv. 2024 November 17.
Customer Validation & Images
-
Cell Migration/Invasion Assay
-
WB
-
RT-PCR
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
All YAP Isoforms
More
Biological Activity
|
YAP/TAZ-TEAD |
TED-347 (0.5-100 μM; 48 hours) inhibits GBM43 cancer cell viability[1].
TED-347 (5 μM; 48 hours) inhibits co-immunoprecipitation of Myc-tagged TEAD4 with FLAG-tagged Yap1[1].
TED-347 (10 μM; 48 hours) shows a significant reduction in CTGF transcript levels[1].
TED-347 (0.5-100 μM; 24 hours) reduces reporter activity in cells transfected with a TEAD reporter. TED-347 (0.5-100 μM) also inhibits TEAD4 transcriptional activity in GBM43 cells[1].
TED-347 is selective for TEADs and inhibits TEAD2 with the same efficacy. TED-347 (0.1-100 μM; 24-48 hours) inhibits TEAD4 binding to full-length Yap1 in dose- and time-dependent manner. TED-347 (1-100 μM) shows no inhibition of uPAR uPA or Cav2.2 α β protein-protein interactions. Non-covalent binding of TED-347 to TEAD4 exhibits little change to the TEAD4 Yap1 binding affinity[1].
TED-347 has the maximum rate of inactivation of 0.038 hours, corresponding to a t1/2∞ of 18.2 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:GBM43 glioblastoma cell lines
-
Concentration:0.5, 1, 10, 100 μM
-
Incubation Time:48 hours
-
Result:Inhibited GBM43 cancer cell viability and inhibited GBM43 cell viability by 30% at 10 μM.
-
Cell Line:HEK-293 cells
-
Concentration:5 μM
-
Incubation Time:48 hours
-
Result:Showed a significant loss of co-immunoprecipitation of Myc-tagged TEAD4 with FLAG-tagged Yap1.
-
Cell Line:HEK-293 cells
-
Concentration:10 μM
-
Incubation Time:48 hours
-
Result:Showed a significant reduction in CTGF transcript levels versus control cells and had no inhibition on TEAD mutant transcriptional activity and protein-protein interactions in cell culture.
Chemical Information
-
CAS No. 2378626-29-8
-
Appearance Solid
-
Molecular Weight 313.70
-
Formula C15H11ClF3NO
-
Color Light yellow to green yellow
-
SMILES
O=C(C1=CC=CC=C1NC2=CC=CC(C(F)(F)F)=C2)CCl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. [Abstract]2024 Mar 9;9(1):65. PMID: 38461173 -
Nat Commun
2024 Nov 16;15(1):9950. PMID: 39550386
TED-347 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 16;15(1):9950. [Abstract]
Transwell migration, invasion, foci formation assays of YAP1 downstream genes following knockdown via shRNAs targeting YAP1 or treatment with two pharmacological YAP-TEAD inhibitors (CA3 and TED-347) in GPRC5A-overexpressing KYSE30 cells.
TED-347 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Nov 16;15(1):9950. [Abstract]
Immunoblotting of YAP1 downstream genes following knockdown via shRNAs targeting YAP1 or treatment with two pharmacological YAP-TEAD inhibitors (CA3 and TED-347) in GPRC5A-overexpressing KYSE30 cells.
-
J Exp Clin Cancer Res
Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. [Abstract]2021 Mar 1;40(1):88. PMID: 33648545
TED-347 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]
RT-PCR analysis was used to detect the mRNA expression levels of CTGF and CYR61 in pancreatic cancer cells infected with sh-Control or sh-WDR3 #1 and treated with or without TED-347 (10 μM).
TED-347 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]
PANC-1 cells infected with sh-Control or sh-WDR3 #1 were subcutaneously injected into nude mice. The mice were treated with TED-347 3 times on days 1, 4, and 7 at a dose of 20 mg/kg. The tumor volume was decreased.
TED-347 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Mar 1;40(1):88. [Abstract]
PANC-1 cells infected with sh-Control or sh-WDR3 #1 and treated with or without TED-347 (10 μM) were harvested for MTS.
-
Prog Orthod
KAT6A/YAP/TEAD4 pathway modulates osteoclastogenesis by regulating the RANKL/OPG ratio on the compression side during orthodontic tooth movement. [Abstract]2024 Aug 12;25(1):29. PMID: 39129034 -
Biochim Biophys Acta Mol Cell Res
Development of a TEAD-independent reporter system for specific and sensitive measurement of YAP/TAZ activity. [Abstract]2026 Mar;1873(3):120111. PMID: 41534572 -
Exp Dermatol
Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers. [Abstract]2022 Oct;31(10):1477-1499. PMID: 35913427 -
FEBS Lett
Pan-cancer multi-omics analyses reveal crosstalk between the Hippo and immune signaling pathways in the tumor microenvironment. [Abstract]2022 Feb;596(4):449-464. PMID: 34855209 -
PLoS One
Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma. [Abstract]2024 Jul 31;19(7):e0305121. PMID: 39083549 -
-
-
Solvent & Solubility
DMSO : 100 mg/mL (318.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.97 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (554 KB)
- English - EN (554 KB)
- Français - FR (554 KB)
- Deutsch - DE (554 KB)
- Norwegian - NO (554 KB)
- Español - ES (554 KB)
- Swedish - SV (554 KB)
- Italian - IT (554 KB)
- Portuguese - PT (554 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1878 mL | 15.9388 mL | 31.8776 mL | 79.6940 mL |
| 5 mM | 0.6376 mL | 3.1878 mL | 6.3755 mL | 15.9388 mL | |
| 10 mM | 0.3188 mL | 1.5939 mL | 3.1878 mL | 7.9694 mL | |
| 15 mM | 0.2125 mL | 1.0626 mL | 2.1252 mL | 5.3129 mL | |
| 20 mM | 0.1594 mL | 0.7969 mL | 1.5939 mL | 3.9847 mL | |
| 25 mM | 0.1275 mL | 0.6376 mL | 1.2751 mL | 3.1878 mL | |
| 30 mM | 0.1063 mL | 0.5313 mL | 1.0626 mL | 2.6565 mL | |
| 40 mM | 0.0797 mL | 0.3985 mL | 0.7969 mL | 1.9923 mL | |
| 50 mM | 0.0638 mL | 0.3188 mL | 0.6376 mL | 1.5939 mL | |
| 60 mM | 0.0531 mL | 0.2656 mL | 0.5313 mL | 1.3282 mL | |
| 80 mM | 0.0398 mL | 0.1992 mL | 0.3985 mL | 0.9962 mL | |
| 100 mM | 0.0319 mL | 0.1594 mL | 0.3188 mL | 0.7969 mL |
Powered by Bioz